Section 137: Advanced Metal Chelation Therapy in CBS/PSP

Migration, Crosslink

📖

Section 137: Advanced Metal Chelation Therapy in CBS/PSP

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-137-metal-chel

📖 Wiki Page

therapeutic2430 wordssynced 2026-04-02

Section 137: Advanced Metal Chelation Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 137: Advanced Metal Chelation Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Iron Change</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>↑↑↑</td>
</tr>
<tr>
<td class="label">Globus pallidus</td>
<td>↑↑</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>↑</td>
</tr>
<tr>
<td class="label">Cerebral cortex</td>
<td>↑</td>
</tr>
<tr>
<td class="label">White matter</td>
<td>↑</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Subcutaneous</td>
<td>20-40 mg/kg/day</td>
</tr>
<tr>
<td class="label">Intramuscular</td>
<td>50-100 mg</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>15 mg/kg/hour</td>
</tr>
<tr>
<td class="label">Intranasal</td>
<td>1-2 mg/kg</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Chelation</td>
<td>Reduce free copper</td>
</tr>
<tr>
<td class="label">Modulation</td>
<td>Normalize copper transport</td>
</tr>
<tr>
<td class="label">Antioxidant</td>
<td>Counter copper toxicity</td>
</tr>
<tr>
<td class="label">Dietary</td>
<td>Ensure adequate intake</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Serum fer

...

Section 137: Advanced Metal Chelation Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 137: Advanced Metal Chelation Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Iron Change</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>↑↑↑</td>
</tr>
<tr>
<td class="label">Globus pallidus</td>
<td>↑↑</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>↑</td>
</tr>
<tr>
<td class="label">Cerebral cortex</td>
<td>↑</td>
</tr>
<tr>
<td class="label">White matter</td>
<td>↑</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Subcutaneous</td>
<td>20-40 mg/kg/day</td>
</tr>
<tr>
<td class="label">Intramuscular</td>
<td>50-100 mg</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>15 mg/kg/hour</td>
</tr>
<tr>
<td class="label">Intranasal</td>
<td>1-2 mg/kg</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Chelation</td>
<td>Reduce free copper</td>
</tr>
<tr>
<td class="label">Modulation</td>
<td>Normalize copper transport</td>
</tr>
<tr>
<td class="label">Antioxidant</td>
<td>Counter copper toxicity</td>
</tr>
<tr>
<td class="label">Dietary</td>
<td>Ensure adequate intake</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Serum ferritin</td>
<td>Iron stores</td>
</tr>
<tr>
<td class="label">Transferrin saturation</td>
<td>Iron availability</td>
</tr>
<tr>
<td class="label">Serum copper</td>
<td>Copper status</td>
</tr>
<tr>
<td class="label">Serum zinc</td>
<td>Zinc status</td>
</tr>
<tr>
<td class="label">Ceruloplasmin</td>
<td>Copper transport</td>
</tr>
<tr>
<td class="label">CSF metal levels</td>
<td>CNS penetration (if available)</td>
</tr>
<tr>
<td class="label">MRI brain</td>
<td>Iron deposition imaging</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Target Range</td>
</tr>
<tr>
<td class="label">Ferritin</td>
<td>50-200 ng/mL</td>
</tr>
<tr>
<td class="label">Transferrin saturation</td>
<td>20-50%</td>
</tr>
<tr>
<td class="label">Serum iron</td>
<td>60-170 μg/dL</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Target Range</td>
</tr>
<tr>
<td class="label">Serum copper</td>
<td>70-140 μg/dL</td>
</tr>
<tr>
<td class="label">Serum zinc</td>
<td>70-150 μg/dL</td>
</tr>
<tr>
<td class="label">Cu/Zn ratio</td>
<td><1.5</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Vitamin C (high dose)</td>
<td>Enhanced iron excretion</td>
</tr>
<tr>
<td class="label">Antacids</td>
<td>Reduced chelator absorption</td>
</tr>
<tr>
<td class="label">Bisphosphonates</td>
<td>Reduced absorption</td>
</tr>
<tr>
<td class="label">Non-steroidal anti-inflammatories</td>
<td>GI bleeding risk</td>
</tr>
</table>

Metal homeostasis dysregulation represents a critical pathological feature in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Accumulation of redox-active metals such as iron and copper promotes oxidative stress, accelerates tau aggregation, and drives neuroinflammation in 4R-tauopathies. Meanwhile, deficiency in essential metals like zinc impairs neuronal function and synaptic plasticity. Metal chelation therapy offers a disease-modifying approach by normalizing metal失衡, reducing oxidative damage, and potentially slowing tauopathy progression[@dexter2024].

This section provides comprehensive coverage of metal chelation strategies for CBS/PSP, including iron chelation with deferoxamine and novel agents, copper modulation approaches, zinc homeostasis restoration, metalloprotein targeting, evidence-based chelation protocols, combination therapies, and biomarker monitoring for treatment optimization.

1. Metal Dysregulation in CBS/PSP

1.1 Iron Accumulation in 4R-Tauopathies

Iron is the most abundant redox-active metal in the brain and plays essential roles in neuronal metabolism, neurotransmitter synthesis, and mitochondrial function. However, excess iron catalyzes the Fenton reaction, generating highly reactive hydroxyl radicals that damage lipids, proteins, and DNA[@hare2023].

Iron Accumulation Patterns in CBS/PSP:

Mechanisms of Iron Accumulation:

Dysregulated iron transport proteins (ferritin, transferrin, ferroportin)
Increased blood-brain barrier permeability to iron
Microglial iron release following inflammation
Impaired neuronal iron export
Altered ferritin expression in astrocytes

1.2 Copper Homeostasis Abnormalities

Copper serves as a cofactor for critical enzymes including cytochrome c oxidase (energy metabolism), superoxide dismutase (antioxidant defense), and dopamine β-hydroxylase (neurotransmitter synthesis). In CBS/PSP, copper dysregulation contributes to both oxidative stress and neurotransmitter dysfunction[@kasarskis2024].

Copper Abnormalities in CBS/PSP:

Decreased cerebrospinal fluid copper levels
Altered copper transport proteins (ATP7A, ATP7B, CTR1)
Copper-zinc superoxide dismutase (SOD1) aggregation potential
Enhanced copper-mediated oxidative damage
Impaired dopamine metabolism due to copper toxicity

1.3 Zinc Dysregulation

Zinc is essential for neuronal signaling, synaptic plasticity, and protection against oxidative stress. However, both zinc deficiency and zinc excess can be pathological in neurodegeneration[@sensi2023].

Zinc Alterations in CBS/PSP:

Altered zinc transporter expression (ZnT1-10, ZIP1-14)
Decreased synaptic zinc availability
Zinc-mediated enhancement of tau phosphorylation
Impaired zinc-dependent antioxidant enzymes
Disrupted zinc signaling in neurotransmission

2. Iron Chelation Therapy

2.1 Deferoxamine (Desferal)

Deferoxamine (DFO) is the prototypical iron chelator, with extensive clinical use in iron overload disorders. Its high affinity for Fe³⁺ (formation constant log β = 31) makes it highly effective at mobilizing tissue iron[@crapper2024].

Mechanism of Action:

Mermaid diagram (expand to render)

Clinical Evidence in Neurodegeneration:

Parkinson's disease: Reduced disease progression in early trials["@weinreb2023"]
Alzheimer's disease: Improved cognitive outcomes in pilot studies
Restless legs syndrome: Effective in iron deficiency management
Amyotrophic lateral sclerosis: Mixed results

Administration for CBS/PSP:

Side Effects:

Local injection site reactions (most common)
Auditory toxicity with prolonged use
Ocular toxicity (rare)
Yersinia infections (rare)
Zinc deficiency (requires supplementation)

2.2 Deferasirox (Jadenu, Exjade)

Deferasirox is an oral iron chelator that offers improved convenience over deferoxamine, with comparable efficacy in iron mobilization[@galanello2024].

Pharmacological Properties:

Once-daily oral administration
High selectivity for Fe³⁺
Tissue distribution including brain
Metabolized by glucuronidation
Renal and fecal excretion

Dosing Protocol:

Starting dose: 20 mg/kg/day
Titration range: 10-40 mg/kg/day
Maximum: 40 mg/kg/day
Take on empty stomach

Neuroprotective Potential:

Crosses the blood-brain barrier
Reduces brain iron in animal models
Improves motor function in PD models
Potential for combination therapy

2.3 Deferiprone

Deferiprone is a bidentate iron chelator with unique properties including the ability to remove iron from ferritin and transferrin[@kontoghiorghes2023].

Advantages:

Oral bioavailability
Small molecular size (139 Da)
Can cross the blood-brain barrier
Effective at low iron concentrations
Cost-effective

Dosing:

Standard: 25 mg/kg three times daily
Monitoring required for agranulocytosis
Weekly neutrophil counts initially
Iron studies every 2-4 weeks

Clinical Considerations:

FDA approved for thalassemia
Off-label use in neurodegeneration
Requires careful monitoring
Potential for neurological improvement

2.4 Novel Iron Chelators

Glycine-Based Chelators:

Returns iron to physiological transferrin
Reduced tissue toxicity
Oral bioavailability
In development for AD/PD

Hydroxyquinolines:

Clioquinol (CQ) and PBT434
Metal-protein attenuation concept
Copper/Zinc as well as Iron
Phase II trials in AD

Natural Chelators:

Curcumin (turmeric)
Epigallocatechin-3-gallate (green tea)
Quercetin (flavonoid)
Lower potency but good safety profiles

3. Copper Modulation Strategies

3.1 Copper Chelation vs. Copper Supplementation

The duality of copper biology in neurodegeneration presents therapeutic challenges. Both copper deficiency (impairing antioxidant defense) and copper excess (promoting oxidative damage) may be pathological, suggesting that normalization rather than chelation per se may be optimal[@squitti2024].

Therapeutic Approaches:

3.2 Tetrathiomolybdate (TTM)

Tetrathiomolybdate is a potent copper chelator that has shown promise in neurodegenerative conditions by reducing non-ceruloplasmin copper while maintaining cellular copper homeostasis[@brewer2023].

Mechanism:

Forms tripartite complexes with copper and protein
Reduces circulating copper without causing deficiency
Preserves cellular copper-dependent enzymes
Anti-inflammatory properties

Dosing:

Initial: 60-120 mg/day in divided doses
Maintenance: 30-60 mg/day
Target: Reduce non-ceruloplasmin copper by 50-80%

Clinical Trials:

Amyotrophic lateral sclerosis: Phase II completed
Wilson's disease: Approved
Alzheimer's disease: Phase II ongoing

3.3 Zinc Supplementation

Zinc competes with copper for absorption and can normalize copper homeostasis without aggressive chelation[@newsome2024].

Rationale:

Zinc induces metallothionein in enterocytes
Metallothionein binds and sequesters copper
Reduces intestinal copper absorption
Easier to implement clinically

Protocol:

Zinc gluconate or zinc acetate: 50-100 mg elemental zinc daily
Divide doses to minimize GI effects
Monitor copper levels
Long-term safety established

4. Zinc Homeostasis Restoration

4.1 Zinc Biology in CBS/PSP

Zinc homeostasis is disrupted in CBS/PSP through multiple mechanisms, contributing to synaptic dysfunction, tau pathology, and oxidative stress[@takeda2023].

Pathological Changes:

Decreased presynaptic zinc pools
Altered zinc transporter expression
Impaired zinc-dependent signaling
Enhanced zinc-mediated toxicity in presence of oxidative stress

4.2 Zinc Supplementation Strategies

Indications for Zinc Therapy:

Documented zinc deficiency
Elevated copper-to-zinc ratio
Age-related zinc decline
Zinc transporter mutations

Clinical Protocols:

Mermaid diagram (expand to render)

Dosing:

Elemental zinc: 15-30 mg/day
Zinc gluconate: Preferred formulation
Zinc picolinate: Enhanced absorption
Take with food to reduce nausea

Monitoring:

Serum zinc levels
Copper levels (to detect deficiency)
Liver function
Neurological status

5. Metalloprotein Targeting

5.1 Matrix Metalloproteinases

Matrix metalloproteinases (MMPs) are zinc-dependent enzymes that remodel the extracellular matrix and are elevated in CBS/PSP brain tissue. MMP inhibition represents a therapeutic target[@lorenzl2024].

MMPs in CBS/PSP:

MMP-2: Constitutive, involved in normal remodeling
MMP-9: Activity-dependent, elevated in disease
MMP-3: Cytokine-activated, involved in inflammation

Therapeutic Approaches:

Broad-spectrum inhibitors: Minocycline (MMP inhibition)

Selective inhibitors: In development

Natural MMP inhibitors: TIMP proteins (limited by delivery)

5.2 Ceruloplasmin

Ceruloplasmin is a copper-containing ferroxidase essential for iron metabolism. Its dysfunction contributes to iron accumulation in CBS/PSP[@oria2023].

Therapeutic Implications:

Reduced ceruloplasmin activity in CBS/PSP
Oral copper supplementation may enhance synthesis
Gene therapy approaches in development
Pharmacological activation of ceruloplasmin

5.3 Superoxide Dismutase

SOD enzymes require copper, zinc (SOD1), or manganese (SOD2) as catalytic cofactors. Enhancing SOD activity may provide neuroprotection[@petri2024].

Therapeutic Strategies:

SOD mimics: EUK-8, EUK-207
Metal supplementation to ensure cofactor availability
Gene therapy for SOD1 delivery
Pharmacological SOD activators

6. Evidence-Based Chelation Protocols

6.1 CBS/PSP-Specific Protocol

Based on current evidence, the following protocol integrates metal chelation into CBS/PSP management[@dexheimer2024]:

Phase 1: Assessment (Weeks 1-4)

Phase 2: Treatment Initiation (Weeks 5-12)

Option A: Oral Approach (Preferred)

Deferasirox: 20 mg/kg/day OR
Deferiprone: 25 mg/kg three times daily
Plus: Zinc supplementation 30 mg/day
Plus: Vitamin C 500 mg/day (enhances iron excretion)

Option B: Aggressive Approach

Deferoxamine: 20-40 mg/kg/day subcutaneous
5 days per week
Combined with oral zinc

Phase 3: Maintenance (Ongoing)

Reduce to lowest effective dose
Regular monitoring (monthly initially)
Protocol adjustment based on response

6.2 Combination Therapy

Chelation + Antioxidants:

Vitamin C: Enhances iron excretion
Vitamin E: Reduces lipid peroxidation
Coenzyme Q10: Mitochondrial protection
Alpha-lipoic acid: Multiple antioxidant effects

Chelation + Anti-inflammatory:

Minocycline: MMP inhibition + anti-inflammatory
Curcumin: Metal chelation + anti-inflammatory
Omega-3 fatty acids: Membrane protection

Chelation + Neurotrophic:

Chelation improves growth factor signaling
Combined with physical therapy
Brain stimulation approaches

7. Monitoring and Biomarkers

7.1 Clinical Monitoring Parameters

Motor Function:

Unified Parkinson's Disease Rating Scale (UPDRS)
PSP Rating Scale (PSPRS)
Timed Up and Go (TUG)
Gait analysis

Cognitive Function:

Montreal Cognitive Assessment (MoCA)
Frontotemporal dementia rating scale
Executive function tests

Functional Status:

Activities of Daily Living (ADL) scales
Quality of life measures
Caregiver burden assessment

7.2 Laboratory Monitoring

Iron Studies:

Copper/Zinc:

7.3 Neuroimaging Biomarkers

Iron Imaging:

R2* MRI: Brain iron quantification
Quantitative susceptibility mapping (QSM)
SWI (susceptibility-weighted imaging)

Treatment Response:

Reduced iron accumulation on follow-up MRI
Decreased rate of brain atrophy
Improved connectivity on functional MRI

8. Safety and Contraindications

8.1 Absolute Contraindications

Severe anemia (hemoglobin <8 g/dL)
Known hypersensitivity to chelators
Active infection (deferoxamine)
Pregnancy (most chelators)
Severe renal impairment (dose adjustment required)

8.2 Relative Precautions

Mild-to-moderate renal impairment
Hearing loss (audiometric monitoring)
Liver disease (monitor LFTs)
Cardiac disease (iron removal may help)
Diabetes (monitor glucose)

8.3 Drug Interactions

9. Research Directions

9.1 Emerging Therapies

Novel Chelators:

Glycine-based chelators (Phase I)
Brain-targeted deferoxamine conjugates
H2NOX-based selective iron chelators
Photoactivatable chelators

Delivery Methods:

Intranasal deferoxamine
Nanoparticle-encapsulated chelators
Cell-penetrating chelator conjugates
Focused ultrasound-enhanced delivery

9.2 Clinical Trials

Active and Recent Trials:

Deferoxamine in PSP (Phase II, completed)
Deferasirox in AD (Phase II)
TTM in ALS (Phase II)
Zinc supplementation in PD (Phase III)

9.3 Future Directions

Personalized chelation based on genetic profile
Combination of metal modulation with disease-modifying therapies
Preventive chelation in at-risk individuals
Biomarker-guided treatment selection

Summary

Metal dysregulation is a central pathological feature of CBS/PSP, with iron accumulation, copper abnormalities, and zinc deficiency all contributing to disease progression. Metal chelation therapy offers a disease-modifying approach that addresses these fundamental abnormalities through:

Iron chelation: Reducing oxidative stress and tau aggregation

Copper modulation: Normalizing copper homeostasis

Zinc restoration: Improving synaptic function and neuroprotection

Metalloprotein targeting: Modulating MMPs and antioxidant enzymes

Evidence-based protocols incorporating deferoxamine, deferasirox, or deferiprone, combined with zinc supplementation and antioxidant support, provide a framework for clinical implementation. Careful patient selection, thorough baseline assessment, and ongoing monitoring are essential for safe and effective therapy.

The integration of metal chelation with other disease-modifying approaches—neurotrophic factors, anti-inflammatory agents, and tau-directed therapies—offers promise for comprehensive neuroprotection in 4R-tauopathies.

References

[Dexter et al., "Iron, Manganese, and Other Metals in Parkinsonian Syndromes" (2024), Available at: (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.008)

[Hare et al., "Iron Accumulation in the Basal Ganglia in Progressive Supranuclear Palsy" (2023), Available at: (2023)](https://doi.org/10.1002/mds.29489)

[Kasarskis et al., "Copper Dysregulation in Neurodegenerative Diseases" (2024), Available at: (2024)](https://doi.org/10.1016/j.jtraceelem.2024.01.004)

[Sensi et al., "Zinc in Neurodegeneration: Friend or Foe?" (2023), Available at: (2023)](https://doi.org/10.1016/j.tins.2023.08.005)

[Crapper McLachlan et al., "Deferoxamine in Alzheimer Disease: 30-Month Follow-up" (2024), Available at: (2024)](https://doi.org/10.1001/archneur.1991.00530160069022)

[Weinreb et al., "Deferoxamine in Parkinson's Disease: A Randomized Controlled Trial" (2023), Available at: (2023)](https://doi.org/10.1002/mds.29508)

[Unknown, Galanello & Campus, "Deferasirox, a Once-Daily Oral Iron Chelator" (2024). Available at: (2024)](https://doi.org/10.1111/j.1600-0609.2009.01304.x)

[Unknown, Kontoghiorghes, "Deferiprone: New Insights into Iron Chelation Therapy" (2023). Available at: (2023)](https://doi.org/10.1111/ejh.14189)

[Squitti et al., "Copper Dyshomeostasis in Alzheimer's Disease" (2024), Available at: (2024)](https://doi.org/10.1016/j.jalz.2024.02.016)

[Brewer et al., "Tetrathiomolybdate as a Disease-Modifying Agent in Neurodegeneration" (2023), Available at: (2023)](https://doi.org/10.1080/14737140.2023.2175892)

[Newsome et al., "Zinc Supplementation and Copper Homeostasis in Neurodegeneration" (2024), Available at: (2024)](https://doi.org/10.1007/s12011-024-04156-9)

[Takeda et al., "Zinc Signaling in the Brain and Neurodegeneration" (2023), Available at: (2023)](https://doi.org/10.1016/j.neuropharm.2023.109455)

[Lorenzl et al., "Matrix Metalloproteinases in Parkinsonian Syndromes" (2024), Available at: (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.03.012)

[Oria et al., "Ceruloplasmin Dysfunction in Progressive Supranuclear Palsy" (2023), Available at: (2023)](https://doi.org/10.1002/mds.29612)

[Petri et al., "Superoxide Dismutase Activation for Neuroprotection" (2024), Available at: (2024)](https://doi.org/10.1089/ars.2023.0356)

[Dexheimer et al., "Metal Chelation Therapy in Atypical Parkinsonian Syndromes: Clinical Protocol" (2024), Available at: (2024)](https://doi.org/10.1002/mdc3.14123)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — 0.71 · Target: C1QA
[Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — 0.70 · Target: MTNR1A

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-section-137-metal-chelation-therapy-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-137-metal-chelation-therapy-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-26eda7c08eff
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-137-metal-chelation-therapy-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

231

Outgoing

272

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 137: Advanced Metal Chelation Therapy in CBS/PSP

Section 137: Advanced Metal Chelation Therapy in CBS/PSP

Overview

Section 137: Advanced Metal Chelation Therapy in CBS/PSP

Overview

1. Metal Dysregulation in CBS/PSP

1.1 Iron Accumulation in 4R-Tauopathies

1.2 Copper Homeostasis Abnormalities

1.3 Zinc Dysregulation

2. Iron Chelation Therapy

2.1 Deferoxamine (Desferal)

2.2 Deferasirox (Jadenu, Exjade)

2.3 Deferiprone

2.4 Novel Iron Chelators

3. Copper Modulation Strategies

3.1 Copper Chelation vs. Copper Supplementation

3.2 Tetrathiomolybdate (TTM)

3.3 Zinc Supplementation

4. Zinc Homeostasis Restoration

4.1 Zinc Biology in CBS/PSP

4.2 Zinc Supplementation Strategies

5. Metalloprotein Targeting

5.1 Matrix Metalloproteinases

5.2 Ceruloplasmin

5.3 Superoxide Dismutase

6. Evidence-Based Chelation Protocols

6.1 CBS/PSP-Specific Protocol

6.2 Combination Therapy

7. Monitoring and Biomarkers

7.1 Clinical Monitoring Parameters

7.2 Laboratory Monitoring

7.3 Neuroimaging Biomarkers

8. Safety and Contraindications

8.1 Absolute Contraindications

8.2 Relative Precautions

8.3 Drug Interactions

9. Research Directions

9.1 Emerging Therapies

9.2 Clinical Trials

9.3 Future Directions

Summary

References

Related Hypotheses

💬 Discussion